2013•Leukemia & lymphoma/Leukemia and lymphomaRequires access

Radioimmunotherapy with90Y-ibritumomab tiuxetan for a hemodialysis patient with relapsed follicular lymphoma

Kenji Fukuno, Hisashi Tsurumi, Toshiki Yamada, Takayoshi Iida, Takeshi Takahashi, Hisataka Moriwaki

Abstract

Yttrium-90 (90Y)-ibritumomab tiuxetan (Y2B8) is a radiolabeled anti-CD20 murine monoclonal antibody. Radioimmunotherapy (RIT) with Y2B8 in patients with relapsed or refractory follicular lymphoma (...

About this research paper

What this paper is about

Why it matters

OpenAlex reports 4 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Radioimmunotherapy, Ibritumomab tiuxetan, Follicular lymphoma, Medicine, Lymphoma, Nuclear medicine, Follicular phase, CD20